Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Feasibility and Efficacy of Brief Behavior Change Counseling on Lifestyle in Hypertensive and Diabetics Participants (BBCC+5A's+GS)

5 de noviembre de 2020 actualizado por: Kamuzu University of Health Sciences

Feasibility and Efficacy of Lifestyle Risk Factors Through Brief Behaviour Change Counseling in NCD's Participants Using 5A's and a Guiding Style (BBCC+ 5A's +GS) in Mangochi, Southern Malawi

The purpose of this study will be to assess the feasibility and the preliminary efficacy of brief behavior change counseling on lifestyle among diabetic and hypertensive patients

Descripción general del estudio

Estado

Desconocido

Intervención / Tratamiento

Descripción detallada

  1. BACKGROUND Noncommunicables diseases (NCDs) are on the rise globally as well as in Malawi, alongside their behavioral modifiable risk factors. Behavioral intervention such as brief behavior change counseling using 5A's and a guiding style (BBCC + 5As +GS) has shown an effect on reducing these lifestyles risk factors. Their effectiveness varies between the behavioral technique used. But So far, available evidences of this effect are from western countries. Even implementation of these techniques has been done in some countries, but so far there is no information about their implementation in noncommunicable diseases field in Mangochi, even Malawi. Therefore, a really need to conduct this study in Mangochi, Southern Malawi.
  2. OBJECTIVES

    1. Overall objective: The primary objective of the study is to test the feasibility of the brief behavior change counseling using 5 A's and a guiding style from motivational interviewing which will be used for NCDs 'patients and assess its efficacy in improving lifestyle risk factors in NCDs' patients.
    2. Specific objectives for this study are

1. to evaluate the feasibility of participating in a future quasi-experimental study of BBCC + 5A's + GS ; 2. to estimate the efficacy of BBCC + 5A's + GS from MI on lifestyle risk factors, theory constructs, quality of life domains; 3. to provide data on which to estimate the sample size required to detect a statistically significant difference between experimental and control groups; 4. and to explore experience of participants and care providers during the brief behaviour change counseling sessions to NCDs' patients in Mangochi

4. Methodology:

  1. Design: mixed methods (pilot quasi-experimental and qualitative study)
  2. Settings: The study will take place at two sites: Mangochi District Hospital and Monkey Bay Community Hospital; Malawi.
  3. sample size: Purposeful sampling and successive eligible patients. Sample size: Efficacy study will be conducted on 50 patients.
  4. Intervention: brief behaviour change using 5A's and a Guiding style from motivational interviewing will be administered to participants in the intervention group by trained counsellors (nurses).

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

50

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Eastern-Region
      • Mangochi, Eastern-Region, Malaui, 42
        • Mangochi District Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • aged between 18-65 years old,
  • registered in the clinic at least for 6 months,
  • been screened for at least 1 lifestyle risk factor,
  • express willingness to participate in the study,
  • being permanent resident in Mangochi District for at least 12 months from recruitment, and
  • Fluent in Chichewa and/or Yao

Exclusion Criteria:

  • - present with any concomitant severe disease,
  • being pregnant
  • patient with an active Psychiatrics' comorbidity

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: BBCC+5A's+GS
Brief behavior change counseling using 5A's + Guiding style (from motivational interviewing) + Printed education materials ( at baseline, 12 weeks, 24 weeks)

It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.

All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information.

Otros nombres:
  • Brief behavior change using 5A's and a guiding style from motivational interviewing
Sin intervención: Normal care
They will receive the normal care: simple advice on changing lifestyle risk factors + medications for diabetes or hypertension ( at baseline, 12 weeks, 24 weeks)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
A measure of participants recruited (recruitment rate)
Periodo de tiempo: [Time frame: through study completion, an average of 24 weeks]
The number of individuals recruited from those eligible
[Time frame: through study completion, an average of 24 weeks]
Number participants who consented to take part in the study
Periodo de tiempo: [Time frame: through study completion, an average of 24 weeks]
The number of participants who accepted to take part in the study from those deemed eligible for the study
[Time frame: through study completion, an average of 24 weeks]
Proportion of participants who completed the study during the 12 weeks' period
Periodo de tiempo: [ time frame: up to 12 weeks]
The number of participants who were able to complete each PROM divided by the total number of participants at 12 weeks
[ time frame: up to 12 weeks]
Proportion of participants who completed the study during the 24 weeks' period
Periodo de tiempo: [ Time frame: through study completion, an average of 24 weeks]
The number of participants who were able to complete each PROM divided by the total number of participants at 24 weeks
[ Time frame: through study completion, an average of 24 weeks]
Proportion of participants retained in the study
Periodo de tiempo: [ Time frame: through study completion, an average of 24 weeks]
Proportion of participants who remained in the study during its full duration. The number of participants who are in the study at 6 months divided by the total number of patients who were recruited
[ Time frame: through study completion, an average of 24 weeks]
Proportions of participant's loss-to-follow-up at 12 weeks
Periodo de tiempo: [ time frame: up to 12 weeks]
Participants who stop (withdraw/dropout) and did not attend the 12 weeks' follow-up visit by the total of recruited participants.
[ time frame: up to 12 weeks]
Loss-to-follow-up at 24 weeks
Periodo de tiempo: [ Time frame: through study completion, an average of 24 weeks]
Participants who stop (withdraw/dropout) and did not attend the 24 weeks' follow-up visit
[ Time frame: through study completion, an average of 24 weeks]

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change from baseline in Alcohol Use Disorder Identification Test-C at 12 weeks
Periodo de tiempo: [ Time frame: at baseline and in 12 weeks]

Audit-C is a validated, self-reported measure of perceived severity (quantity and frequency) of consumption of alcohol comprising 3 questions whose score gives a global score from the 3.

The scoring system of AUDIT-C is as follow: frequency of drink containing alcohol (scores: 0-4); number of standard drinks on a day (scores: 0-4); and frequency of 5 or more standard drinks on any one occasion (scores: 0-4). This global score is either below 5 (non-harmful alcohol use), or from 5 and higher (harmful alcohol). The higher the score, the severe the drinking.

[ Time frame: at baseline and in 12 weeks]
Alcohol Use Disorder Identification Test-C at 24 weeks
Periodo de tiempo: [ Time frame: through study completion, an average of 24 weeks]

Mean change from baseline of Alcohol Use Disorder Identification Test among participants who were screened for harmful alcohol use with a score of 5 or more on AUDIT-C at 24 weeks. 9. Change from baseline in Alcohol Use Disorder Identification Test-C at 12 weeks Audit-C is a validated, self-reported measure of perceived severity (quantity and frequency) of consumption of alcohol comprising 3 questions whose score gives a global score from the 3.

The scoring system of AUDIT-C is as follow: frequency of drink containing alcohol (scores: 0-4); number of standard drinks on a day (scores: 0-4); and frequency of 5 or more standard drinks on any one occasion (scores: 0-4). This global score is either below 5 (non-harmful alcohol use), or from 5 and higher (harmful alcohol). The higher the score, the severe the drinking.

[ Time frame: through study completion, an average of 24 weeks]
Mean change in smoking from baseline to 12 weeks using Short Fagerström Test for Nicotine dependence among participants who are screened for smoking of any form (cigarettes, chewing, tobacco, pipe) and any amount out at 24 weeks
Periodo de tiempo: [ Time frame: at baseline and 24 weeks]
Fagertrom test using two questions for scoring related to time between walking-up and taking the first cigarettes (≤ 5 min= 3, 6-30 minutes=1, 31-60 minutes=3), and number of cigarettes taken per day (≤ 10=0, 11-20=1, 21-30=2, and ≥ 31=3). score varies from 0-6; 0-3=very low risk and 6= very high risk
[ Time frame: at baseline and 24 weeks]
Mean change in smoking from 12 weeks to 24 weeks using Short Fagerström Test for Nicotine dependence
Periodo de tiempo: [ Time frame: at 12 weeks and 24 weeks]
Mean change in smoking from baseline to 12 weeks using Short Fagerström Test for Nicotine dependence among participants who are screened for smoking of any form (cigarettes, chewing, tobacco, pipe) and any amount out at 24 weeks. Fagertrom test using two questions for scoring related to time between walking-up and taking the first cigarettes (≤ 5 min= 3, 6-30 minutes=1, 31-60 minutes=3), and number of cigarettes taken per day ( ≤ 10=0, 11-20=1, 21-30=2, and ≥ 31=3). score varies from 0-6; 0-3=very low risk and 6= ery high risk
[ Time frame: at 12 weeks and 24 weeks]
16. Change from 12 weeks in health-related quality of life using the World Health Organization quality of life tool (WHOQOL-Bref)
Periodo de tiempo: [Timeframe baseline, 12 weeks]

WHOQoL-Bref is a validated, self-reported instrument that is a general measure of perceived health status comprising 26 questions and yielding to 5 scores from 5 dimensions (with subscales) that assess 5 dimensions, namely: mobility; self-care; usual activities; pain/discomfort; and anxiety/ depression. Each dimension has 3 levels: no problems, some problems, and extreme problems, with scores of 1, 2, and 3 representing each level, respectively. The Global score is given by the sum of scores in each dimension/domain. The change will be the differences in scores between the figures at 24 weeks' menus figures at 12 weeks. The low the score, the worse the quality of life.

Score is given by the sum of scores in each dimension/domain. The change will be the differences in scores between the figures at 12 weeks' menus figures at baseline. The low the score, the worse the quality of life.

[Timeframe baseline, 12 weeks]
Change from baseline in health-related quality of life using the World Health Organization quality of life tool (WHOQOL-Bref)
Periodo de tiempo: [Timeframe: baseline and in 6 weeks]

WHOQoL is a validated, self-reported instrument that is a general measure of perceived health status comprising 26 questions and yielding to 5 scores from 5 dimensions (with subscales) that assess 5 dimensions, namely: mobility; self-care; usual activities; pain/discomfort; and anxiety/ depression. Each dimension has 3 levels: no problems, some problems, and extreme problems, with scores of 1, 2, and 3 representing each level, respectively.

The Global score is given by the sum of scores in each dimension/domain. The change will be the differences in scores between the figures at 12 weeks' menus figures at baseline. The low the score, the worse the quality of life.

[Timeframe: baseline and in 6 weeks]
Change in theory of planned behavior constructs' scores from baseline to 12 weeks
Periodo de tiempo: [Timeframe: baseline, 12 weeks]
18. Change in theory of planned behavior constructs' scores from baseline to 12 weeks The theory of planned behavior posits that he fact for someone to perform a given behavior (example: adopts a healthy diet) is guided by three kinds of considerations: beliefs about the likely consequences and experiences associated with the behavior (behavioral beliefs), beliefs about the normative expectations and behaviors of significant others (normative beliefs), and beliefs about the presence of factors that may facilitate or impede performance of the behavior (control beliefs). To measure those three components, a 7 points-scale was applied to each behavior with high number representing better (positive numbers)/worse outcomes (negative numbers). For attitude: bad-good; pleasant-unpleasant For perceived norm (agree-disagree; unlikely-likely), for perceived behavioral control (true-false, disagree-agree); intension (likely-unlikely, false-true) . The higher the score, the better
[Timeframe: baseline, 12 weeks]
Change in theory of planned behavior constructs' means' difference from 12 to 24 weeks
Periodo de tiempo: [Timeframe: 12 weeks through 24 weeks]

The theory of planned behavior posits that he fact for someone to perform a given behavior (example: adopts a healthy diet) is guided by three kinds of considerations: beliefs about the likely consequences and experiences associated with the behavior (behavioral beliefs), beliefs about the normative expectations and behaviors of significant others (normative beliefs), and beliefs about the presence of factors that may facilitate or impede performance of the behavior (control beliefs).

To measure those components, a 7 points-scale was applied to each behavior with high number representing better (positive numbers)/worse outcomes (negative numbers).

Descriptive statistics per constructs were calculated. For attitude: bad-good; pleasant-unpleasant; for perceived norm (agree-disagree; unlikely-likely); for perceived behavioral control (true-false, disagree-agree); and intension (likely-unlikely, false-true)

[Timeframe: 12 weeks through 24 weeks]
To assess the change of the the theory of planned behavior constructs between baseline scores and 24 weeks'
Periodo de tiempo: [Time frame: 12, 24 weeks]

The theory of planned behavior posits that he fact for someone to perform a given behavior (example: adopts a healthy diet) is guided by three kinds of considerations: beliefs about the likely consequences and experiences associated with the behavior (behavioral beliefs), beliefs about the normative expectations and behaviors of significant others (normative beliefs), and beliefs about the presence of factors that may facilitate or impede performance of the behavior (control beliefs).

To measure those components, a 7 points-scale was applied to each behavior with high number representing better (positive numbers)/worse outcomes (negative numbers).

Descriptive statistics per constructs were calculated. For attitude: bad-good; pleasant-unpleasant; for perceived norm (agree-disagree; unlikely-likely); for perceived behavioral control (true-false, disagree-agree); and intension (likely-unlikely, false-true)

[Time frame: 12, 24 weeks]
Change of Trans theoretical model (TTM) stage from baseline to 12 weeks in the "Theoretical Model of Change" score
Periodo de tiempo: [time frame: baseline, 12 weeks]

Change of Trans theoretical model (TTM) stage from baseline to 12 weeks in the "Theoretical Model of Change" score TTM is a validated, self-report tool used to detect the level of change a participant has at a given time. For our case at baseline, 12 weeks, and at 24 weeks) scored from 1 to 5. Comparison of the scoring at 12 and at 24 will show if there has been change or not.

The staging system of TTM is as follow

  1. STAGE 1; pre contemplation: I do not intend in the next 6 months
  2. stage 2. Contemplation: I intend to in the next 6 months
  3. stage 3. Preparation: I intend to in the next 30 days
  4. stage 4. Action: have been doing so for less than 6 months
  5. stage 5 maintenance I have been doing so for more than 6 months The higher the stage, the advanced the degree of changes and vice-versa. Same figure at two different time points= no progress on degree of behavior change.
[time frame: baseline, 12 weeks]
Change of TTT sub-scales means from 12 to 24 weeks in the "Theoretical Model of Change" scores
Periodo de tiempo: [Time frame: 12 weeks and 24 weeks]

Change of Trans theoretical model (TTM) stage from baseline to 12 weeks in the "Theoretical Model of Change" score TTM is a validated, self-report tool used to detect the level of change a participant has at a given time. For our case at baseline, 12 weeks, and at 24 weeks) scored from 1 to 5. Comparison of the scoring at 12 and at 24 will show if there has been change or not.

The staging system of TTM is as follow

  1. STAGE 1; pre contemplation: I do not intend in the next 6 months
  2. stage 2. Contemplation: I intend to in the next 6 months
  3. stage 3. Preparation: I intend to in the next 30 days
  4. stage 4. Action: have been doing so for less than 6 months
  5. stage 5 maintenance I have been doing so for more than 6 months The higher the stage, the advanced the degree of changes and vice-versa. Same figure at two different time points= no progress on degree of behavior change.
[Time frame: 12 weeks and 24 weeks]

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
change from baseline in body weight at 12 weeks
Periodo de tiempo: [Time frame: baseline and 12 weeks]
The measure will be assessed in the morning before the clinic, participants will be weighted in light clothes, barefoot using bathroom scale and will be recorded to the nearest 0.1 kg. Change will be calculated as the difference of weight recorded at baseline and weight recorded at 12 weeks.
[Time frame: baseline and 12 weeks]
Change of body weight from 12 weeks at 24 weeks
Periodo de tiempo: [Time frame 12 and 24 weeks]
The measure will be assessed in the morning before the clinic, participants will be weighted in light clothes, barefoot using bathroom scale and will be recorded to the nearest 0.1 kg. Change will be the difference of weight recorded at 12 weeks and weight recorded at 24 weeks.
[Time frame 12 and 24 weeks]
Mean's change from baseline in Body Mass Index at 12 weeks
Periodo de tiempo: [Time Line: baseline and 12 weeks]
The measure will be assessed after measurements of weight (kilograms) and height (meters) by dividing the weight square by the root-square of height (in meters). The values of below 18.5= underweight, 18.5-25= healthy weight, 25-29.9= overweight, and 30-35 = Grade I, 35-40: Grade II.,, ≥ 40: Grade III. Change will be the difference of BMI calculated at baseline and at 12 weeks. The higher the figure after 25, the worse the outcome.
[Time Line: baseline and 12 weeks]
Mean's Change from 12 weeks in Body Mass Index to 24 weeks
Periodo de tiempo: [Time Line: 12 weeks and 24 weeks]

The measure will be assessed after measurements of weight (kilograms) and height (meters) by dividing the weight square by the root-square of height (in meters). The values of below 18.5= underweight, 18.5-25= healthy weight, 25-29.9= overweight, and 30-35 = Grade I, 35-40: Grade II.,, ≥ 40: Grade III.

Change will be the difference of BMI calculated at 12 weeks with the figure at 24 weeks. The higher the figure after 25, the worse the outcome. The higher the figure after 25, the worse the outcome

[Time Line: 12 weeks and 24 weeks]
Means' Change from baseline in Body Mass Index to 24 weeks
Periodo de tiempo: [Time Frame: baseline and 24 weeks]
The measure will be assessed after measurements of weight (kilograms) and height (meters) by dividing the weight square by the root-square of height (in meters). The values of below 18.5= underweight, 18.5-25= healthy weight, 25-29.9= overweight, and 30-35 = Grade I, 35-40: Grade II.,, ≥ 40: Grade III. Change will be the difference of BMI calculated at baseline with the figure at 24 weeks. The higher the figure after 25, the worse the outcome
[Time Frame: baseline and 24 weeks]
Means' Change in waist -to- hip ratio at 12 weeks
Periodo de tiempo: [Time Line: baseline and 12 weeks]
Hip measurements were taken using a tape-measure placed horizontally at the point of maximum circumference over the buttocks. Measurements were taken to the nearest 0.1 cm.
[Time Line: baseline and 12 weeks]
Mean's change in Mean waist-to-hip ratio (WHR) at 12 weeks
Periodo de tiempo: [ Time Frame: baseline and 12 weeks]

The measure will be assessed by dividing the waist circumference (using a tape-measure placed horizontally at the point between the iliac crest process and the lower margin of the last palpable rib in a patient standing on deep respiratory) by the hip circumference (Hip measurements were taken using a tape-measure placed horizontally at the point of maximum circumference over the buttocks) on a standing-up participants in deep expiration.

The normal range value is 0.80- 0.75. High values Change will be the difference of WHR calculated at baseline with the figure at 24 weeks.

[ Time Frame: baseline and 12 weeks]
Mean's change in Mean waist-to-hip ratio at 24 weeks
Periodo de tiempo: [ Time Frame: baseline and 24 weeks]

The measure will be assessed by dividing the waist circumference (using a tape-measure placed horizontally at the point between the iliac crest process and the lower margin of the last palpable last rib in a patient standing on deep respiratory) by the hip circumference (Hip measurements were taken using a tape-measure placed horizontally at the point of maximum circumference over the buttocks) on a standing-up participants in deep expiration.

The normal range value from 0.80 to 0.70 More than……… central obesity. Change will be the difference of WRH calculated at 12 weeks and that at 24 weeks.

[ Time Frame: baseline and 24 weeks]
Means' Change from baseline in pulse rate using an electronic blood pressure machine
Periodo de tiempo: [Time frame: baseline and 12 weeks]

This measure was assessed in the morning before the clinic alongside with the blood pressure recording through an electronic machine which is recording concurrently the blood pressure reading and the pulse rate. The normal values vary between 60-100, beyond which we have a tachycardia in adults, and below we note a bradycardia.

The value change was calculated as the value recorded at baseline minus the value recorded before any clinical examination at 12 weeks.

[Time frame: baseline and 12 weeks]
Means' change from 12 weeks in pulse rate using an electronic blood pressure machine
Periodo de tiempo: [Time frame: 12 and 24 weeks]

This measure was assessed in the morning in patient relaxed in seating position before the clinic alongside with the blood pressure. The third recorded pulse rate's reading from the battery powered digital blood pressure machine was recorded. The normal values varied between 60-100, beyond which we have a tachycardia in adults, and below we note a bradycardia.

The value change was calculated as the value recorded at 12 weeks minus the value recorded at 24 weeks.

[Time frame: 12 and 24 weeks]
34. Means' change from baseline in the mean pulse rate to 24 weeks using an electronic blood pressure machine
Periodo de tiempo: [Time frame: baseline and 24 weeks]

This measure was assessed in the morning before the clinic alongside with the blood pressure. The third recorded pulse rate's reading from the battery powered digital blood pressure machine was recorded. The normal values vary between 60-100, beyond which we have a tachycardia in adults, and below we note a bradycardia.

The value change was calculated as the value recorded at baseline minus the value recorded before at 24 weeks.

[Time frame: baseline and 24 weeks]
35. Means' Change from baseline in the seated through cuff mean systolic blood pressure (SBP) from baseline to 12 weeks
Periodo de tiempo: [Time Frame: baseline and 12 weeks]
The difference of the mean of third and second recorded systolic blood pressure readings on a seated relaxed patient from the battery powered digital blood pressure machine was recorded.
[Time Frame: baseline and 12 weeks]
Mean's change from 12 weeks in the seated patient through cuff mean systolic blood pressure from 12 to 24 weeks
Periodo de tiempo: [Time Frame: 12 weeks and 24 weeks]
The difference of the means of third and second recorded systolic blood pressure readings of the 12 and 24 weeks on a seated relaxed patient from the battery powered digital blood pressure machine was recorded.
[Time Frame: 12 weeks and 24 weeks]
Mean's change from baseline in the seated through cuff mean systolic blood pressure (SBP) from baseline to 12 weeks
Periodo de tiempo: [Time Frame: baseline and 12 weeks]
The difference of the mean of third and second recorded systolic blood pressure readings on a seated relaxed patient from the battery powered digital blood pressure machine was recorded.
[Time Frame: baseline and 12 weeks]
Mean's change from baseline in the seated patient through cuff mean systolic blood pressure from 0 to 24 weeks
Periodo de tiempo: [Time Frame: baseline and 24 weeks]
The difference of the means of third and second recorded systolic blood pressure readings of the 0 and 24 weeks on a seated relaxed patient from the battery powered digital blood pressure machine was recorded.
[Time Frame: baseline and 24 weeks]
Mean's change from baseline in the seated through cuff mean diastolic blood pressure (SBP) from baseline to 12 weeks
Periodo de tiempo: [Time Frame: baseline and 12 weeks]
The difference of the mean of third and second recorded diastolic blood pressure readings on a seated relaxed patient from the battery powered digital blood pressure machine was recorded.
[Time Frame: baseline and 12 weeks]
Mean's change from 12 weeks to 24 weeks in the seated patient through cuff mean diastolic blood pressure
Periodo de tiempo: [Time Frame: 12 weeks and 24 weeks]
The difference of the means of third and second recorded diastolic blood pressure readings of the 12 and 24 weeks on a seated relaxed patient from the battery powered digital blood pressure machine was recorded.
[Time Frame: 12 weeks and 24 weeks]
Means' change from baseline in the seated patient through cuff mean diastolic blood pressure from 0 to 24 weeks
Periodo de tiempo: [Time Frame: baseline and 24 weeks]
The difference of the means of third and second recorded systolic blood pressure readings of the 0 and 24 weeks on a seated relaxed patient from the battery powered digital blood pressure machine was recorded.
[Time Frame: baseline and 24 weeks]
Means' change from baseline in the level of fasting blood sugar (mg/dl)
Periodo de tiempo: [Time-line: baseline, 12 weeks]
Clinical chemistry laboratory test of blood sugar assesses using blood samples. The normal values are between 70 and 115 mg/dl. FBS≥ 115 = abnormal
[Time-line: baseline, 12 weeks]
Means change from 12 weeks in the level of fasting blood sugar (mg/dl)
Periodo de tiempo: [Time-line: 12 weeks, 24 weeks]
Clinical chemistry laboratory test of blood sugar assessment using blood samples. The normal values are between 70 and 115 mg/dl. FBS≥ 115 = abnormal.
[Time-line: 12 weeks, 24 weeks]
Means change from baseline in the level of fasting blood sugar (mg/dl)
Periodo de tiempo: [Time-line: 12 weeks, 24 weeks]
Clinical chemistry laboratory test of blood sugar assessment using blood samples. The normal values are between 70 and 115 mg/dl. FBS≥ 115 = abnormal
[Time-line: 12 weeks, 24 weeks]
Means change from baseline to 12 weeks in the level of total cholesterol (TC) (mg/dl)
Periodo de tiempo: [Time line: baseline, 12 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 200 mg/dl; beyond which you have hypercholesterolemia
[Time line: baseline, 12 weeks]
Means change from 12 weeks to 24 in the level of total cholesterol (TC) (mg/dl)
Periodo de tiempo: [Time line: 12 weeks and 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 200 mg/dl; beyond which you have hypercholesterolemia
[Time line: 12 weeks and 24 weeks]
Means change from baseline to 24 weeks in the level of total cholesterol (TC) (mg/dl)
Periodo de tiempo: [Time line: baseline, 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values < 200 mg/dl; beyond which you have hypercholesterolemia
[Time line: baseline, 24 weeks]
Means change from baseline to 12 weeks in the level of High density lipoproteins (HDL) (mg /dl)
Periodo de tiempo: [Time line: baseline, 12 weeks]
Change from baseline to 12 weeks in the level of high density lipoproteins (HDL) (mmol/dl) Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ >1.15 millimole per deciliter; beyond which you have high HDL
[Time line: baseline, 12 weeks]
Means change from 12 weeks to 24 in the level of High density lipoproteins (HDL) (mg/dl)
Periodo de tiempo: [Time line: 12 weeks and 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 150 mg/dl; beyond which you have high HDL.
[Time line: 12 weeks and 24 weeks]
Means change from baseline to 24 weeks in the level of High density lipoproteins (HDL) (mg/dl)
Periodo de tiempo: [Time line: baseline, 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 150 mg/dl; beyond which you have high HDL
[Time line: baseline, 24 weeks]
Means change from baseline to 12 weeks in the level of low density lipoproteins (LDL) (mg/dl)
Periodo de tiempo: [Time line: baseline, 12 weeks]
Change from baseline to 12 weeks in the level of low density lipoproteins (LDL) (mg/dl) Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 150 mg/dl; beyond which you have high LDL.
[Time line: baseline, 12 weeks]
Means change from 12 weeks to 24 in the level of low density lipoproteins (LDL) (mg/dl)
Periodo de tiempo: [Time line: 12 weeks and 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 150 mg/dl; beyond which you have high LDL.
[Time line: 12 weeks and 24 weeks]
Means change from baseline to 24 weeks in the level of Low density lipoproteins (LDL) (mg/dl)
Periodo de tiempo: [Time line: baseline, 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 150 mg/dl; beyond which you have high LDL
[Time line: baseline, 24 weeks]
Means change from baseline to 12 weeks in the level of triglycerides (TGC) (mg/dl)
Periodo de tiempo: [Time line: baseline, 12 weeks]
Change from baseline to 12 weeks in the level of triglycerides (TGC) (mg/dl) Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 203.5 mg/dl; beyond which you have high TGC
[Time line: baseline, 12 weeks]
Means change from 12 weeks to 24 in the level of triglycerides (TGC) (mg/dl)
Periodo de tiempo: [Time line: 12 weeks and 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 203 mg/dl; beyond which you have high TGC
[Time line: 12 weeks and 24 weeks]
Means change from baseline to 24 weeks in the level of triglycerides (TGC) (mg/dl).
Periodo de tiempo: [Time line: baseline, 24 weeks]
Clinical chemistry laboratory test of lipids products assessment using blood sample. The normal value is values ≤ 203.5 mg/dl; beyond which you have high TGC
[Time line: baseline, 24 weeks]

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Adamson S Muula, PhD, Kamuzu University of Health Sciences

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

13 de agosto de 2020

Finalización primaria (Anticipado)

23 de febrero de 2021

Finalización del estudio (Anticipado)

30 de marzo de 2021

Fechas de registro del estudio

Enviado por primera vez

19 de agosto de 2020

Primero enviado que cumplió con los criterios de control de calidad

5 de noviembre de 2020

Publicado por primera vez (Actual)

12 de noviembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2020

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2020

Última verificación

1 de noviembre de 2020

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • P.08/18/2454
  • 5U24HL136791-01 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

Descripción del plan IPD

all IPD that underlie results in a publication

Marco de tiempo para compartir IPD

6 months after publication

Criterios de acceso compartido de IPD

will to learn more or clarification on results will prompt to share IPD,all data data which may assist in clear understanding of the results. Once the request sent, it will be reviewed by the principal investigator. The criteria to review he request will be the seriousness of the request ( either in understanding the study or verification of the results, or will to reproduce the study within the ethical criteria regulations.

Tipo de información de apoyo para compartir IPD

  • Plan de Análisis Estadístico (SAP)
  • Informe de estudio clínico (CSR)
  • Código analítico

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre BBCC+5A's+GS

3
Suscribir